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Abstract
We previously reported on the outcome of 21 patients with stage IV advanced and/or recurrent tongue base
carcinoma subjected to mTHPC-PDT. We continue to develop on the previous work by treating more patients with
this unforgiving disease. PDT has shown to be a very successful minimally-invasive surgical tool in managing this
pathology. Tumour-associated symptoms were reduced significantly. The overall morbidity and mortality following
PDT, in this group of patients, were far less when compared with other conventional modalities.
Background
We reported, in a preliminary study, on the use of PDT as
a minimally-invasive surgical intervention for advanced
and/or recurrent tongue base carcinoma [1]. Twenty-one
patients with this unforgiving disease were subjected to
mTHPC-US-guided interstitial PDT, the cohort was
followed-up for a mean of 36 months (min. 21, max. 45).
Tumour response to PDT was remarkable with the major-
ity of the patients reporting reduction of tumour-asso-
ciated symptoms (P<0.001) (i.e. breathing, swallowing and
speech problems). This was confirmed clinically and radi-
ologically. Mortality figures showed that 4 patients died
from loco-regional disease spread and further 2 from an
existing distant tumour spread.
Aims
In order to encourage evidence-based practice in surgery,
and to ensure that the treatment and processes are sound,
we developed upon the work of the preliminary study, col-
lecting data from a larger recruit (33 patients in total).
Patients’ reports on quality of life with clinical and radiolo-
gical evaluation were used to assess the outcome.
Materials and methods
All the 33 (23 males and 10 females) treated patients
with advanced and/or recurrent tongue base carcinoma
(stage IV) were discussed at the UCLH multidisciplinary
meeting. The mean age was 77.5 +/- 8.3 years (min. 48,
max. 92) with 90% being Caucasians.
The patients’ main complaints were categorized into
three parameters: breathing, swallowing and speech pro-
blems. Problems associated with pathological growth in
the oro-pharyngeal/laryngeal regions caused breathing
problems in 14 patients, swallowing problems in 33
patients, and speech (voice) problems in 18 patients. As
there is no current verified assessment of quality of life in
patients undergoing PDT, the patients were asked only to
report the nature of the complaint and not the severity
It was agreed to offer interstitial PDT (iPDT) under gen-
eral anaesthesia, using mTHPC as the photosensitising
agent. mTHPC 0.15 mg/kg was administered into the
mid-cubital vein 96 hours prior to treatment. Also, 35
metastatic cervical lymph nodes were identified and
treated.
Intra-operatively, an ultrasound probe was used to
examine the centre and periphery of the pathological tis-
sue assessing volume, depth, invasion of vascular struc-
tures, hollow organs and/or hard tissue. This was followed
by insertion of 18 Gauge 70 mm long spinal needles under
US-guidance into the target tissue.
Iso-illumination treatment plan was carefully implemen-
ted and supervised by a senior physicist. A four-channel
652 nm diode laser was used for illumination. Bare
polished-tip laser-light delivery fibres, with a core diameter
of 400 μm, were introduced through the spinal needles
into the tumour. Light was then delivered from the fibres
to the target tissue at 20 J per site (cm2).
Postoperatively, gradual light re-exposure and airway
and pain control was the priority. Twelve of our patients
underwent elective tracheostomy prior to iPDT and 8
others had nasopharyngeal tube inserted. Patients were
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discharged from hospital care at a mean of 10 days
(Min 7, max 22) postoperatively. Patients were followed-
up and asked to report on the outcome of their therapy.
Clinical assessment outcome was performed by a team of
surgeons/physicians trained in photodynamic therapy at
approximately 6 weeks postoperatively. MR imaging was
performed 5-6 weeks postoperatively. Patients were fol-
lowed-up for a mean of 48 months (Min 22, Max 72).
Statistical Analysis
This was performed using the SPSS 17 program (statistical
package for social scientists) by an independent statistician.
The patients’ data were entered onto proformas which
were validated and checked by interval sampling. The fields
included a range of clinical, operative, and radiological
parameters related to the outcome following PDT. The
results were cross tabulated and the Chi-squared statistic
was used to test for differences in the incidence of outcome.
Fisher’s exact test was used for the analysis of contingency
tables and therefore to measure the P-value. Cross tabula-
tion was also used to compare complications, survival, and
cause of death to clinical and radiological assessment.
Results
The majority of the patients (11/14) reported improve-
ment of breathing (P<0.001), with one patient reporting
worsening of symptoms. An improvement of swallowing
was reported by 28/33 patients (P<0.001); while speech
improvement was evident in 15/18 patients (P<0.001).
Clinical assessment showed that two-thirds of the patients
had “good response” to the treatment and a third reported
“moderate response”.
Radiological assessment comparing imaging 6-week
post-PDT to the baseline showed stable pathology with no
change in size in 6 patients, minimal response (<25%
reduction) in 7 patients, moderate response (<50% reduc-
tion) in 12 patients and significant response (50-75%
reduction) in 8 patients. Thirty-five cervical lymph nodes
were subjected to PDT and most of them (P<0.001)
become necrotic with either no change or reduction in
size.
About 90% of our patients reported no problems follow-
ing PDT. Unfortunately, due to the extended duration of
skin photosensitization following treatment, skin burn was
reported by six of our patients; while two patients had skin
necrosis caused by treating pathologies very close to the
surface.
Fourteen patients needed only one round of iPDT to
shrink and control the disease and prevent further pro-
gression, while the rest needed two to three rounds of
treatment. Follow-up at a mean of 48 months (Min 22,
Max 72). revealed eleven mortalities. Cancer-related mor-
talities included seven from loco-regional disease spread
and two from ongoing distant metastasis.
Conclusion
In the current short communication, the cohort was a
group of patients with locally advanced and/or recurrent
tongue base carcinoma. All failed to respond to the con-
ventional treatment modalities or presented so late that
were only offered a palliative route. These patients were
likely to resist further treatment and are expected to
have a very short life expectancy (less than 6 months)
with high morbidity.
Here the results showed that the treatment was well-
tolerated by all patients and very effective in shrinking
tumour and controlling further progression. The great
utility of this intervention is not only in its repeatability
(unlike radiotherapy) but in the accuracy of treatment.
The overall morbidity and mortality after PDT, in this
group of patients, were far less when compared with
other conventional modalities.
To sum up, the growing body of evidence regarding the
successful clinical application of PDT in the management
of tissue pathology should encourage clinicians to offer
this modality as one of the options when dealing with
complicated pathologies. The ability to guide the treat-
ment intra-operatively under ultrasound guidance allows
it a leading role in interventional surgical oncology. PDT
is a successful modality in the treatment of advanced and/
or recurrent tongue base carcinoma. The clinical and radi-
ological end-point parameters are, in fact, very promising
for such end-stage disease group.
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